Previous Article | Next Article 
J Virol, January 1998, p. 388-395, Vol. 72, No. 1
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Transforming Potential of the Herpesvirus
Oncoprotein MEQ: Morphological Transformation, Serum-Independent
Growth, and Inhibition of Apoptosis
Juinn-Lin
Liu,1,2
Ying
Ye,3
Lucy F.
Lee,2 and
Hsing-Jien
Kung1,*
Department of Molecular Biology and
Microbiology, School of Medicine, Case Western Reserve University,
Cleveland, Ohio 44106-49601;
Department
of Cancer Biology, Cleveland Clinic Foundation, Cleveland, Ohio
441953; and
Avian Disease and Oncology
Laboratory, Agricultural Research Station, U.S. Department of
Agriculture, East Lansing, Michigan 488232
Received 24 July 1997/Accepted 26 September 1997
 |
ABSTRACT |
Marek's disease virus (MDV) induces the rapid development of
overwhelming T-cell lymphomas in chickens. One of its candidate oncogenes, meq (MDV Eco Q) which encodes a bZIP protein,
has been biochemically characterized as a transcription factor.
Interestingly, MEQ proteins are expressed not only in the nucleoplasm
but also in the coiled bodies and the nucleolus. Its novel subcellular localization suggests that MEQ may be involved in other functions beyond its transcriptional potential. In this report we show that MEQ
proteins are expressed ubiquitously and abundantly in MDV tumor cell
lines. Overexpression of MEQ results in transformation of a rodent
fibroblast cell line, Rat-2. The criteria of transformation are based
on morphological transfiguration, anchorage-independent growth, and
serum-independent growth. Furthermore, MEQ is able to distend the
transforming capacity of MEQ-transformed Rat-2 cells through inhibition
of apoptosis. Specifically, MEQ can efficiently protect Rat-2 cells
from cell death induced by multiple modes including tumor necrosis
factor alpha, C2-ceramide, UV irradiation, and serum deprivation. Its
antiapoptotic function requires new protein synthesis, as treatment
with a protein synthesis inhibitor, cycloheximide, partially reversed
MEQ's antiapoptotic effect. Coincidentally, transcriptional induction
of bcl-2 and suppression of bax are also
observed in MEQ-transformed Rat-2 cells. Taken together, our results
suggest that MEQ antagonizes apoptosis through regulation of its
downstream target genes involved in apoptotic and/or antiapoptotic
pathways.
 |
INTRODUCTION |
Marek's disease virus (MDV) is one
of the most potent oncogenic viruses, and it induces the rapid onset of
T-cell lymphomas and a demyelinating disease (for reviews, see
references 7, 20, and
38). Recent studies have revealed several candidate viral genes involved in the oncogenic process (for a review, see reference 24). Among these potential oncogenes,
meq (MDV Eco Q) is most consistently expressed in all tumor
and transformed cell lines (19, 37, 47). Furthermore, Xie et
al. (52) recently used an antisense strategy to show that
MEQ is required for the maintenance of the transformed state of an MDV
tumor cell line, MSB1. MEQ has been biochemically characterized as a
transcription factor (39). Its N-terminal basic
region-leucine zipper (bZIP) domain has homology with the Jun/Fos
family of transcription factors. The C-terminal transactivation domain
is rich in proline residues with unique two and one-half repeats
(19). There are two potential DNA response elements,
namely, MERE1 (GAGTGATGA[C/G]TCATC) and MERE2 (PuACACACPy) (40), to which MEQ can bind
and thereupon regulate both viral and host gene expression.
Interestingly, MEQ localizes not only to the nucleus but also to the
nucleolus and coiled bodies (27). Its novel subnuclear
localization implies certain uncharacterized functions beyond its
transcriptional potential. There are two clusters of arginine and
lysine residues in the basic region of MEQ, namely, basic region 1 (BR1) and BR2. BR2 has been mapped to be the major nuclear
localization signal and the sole nucleolar localization signal, while
BR1 provides an auxiliary signal for nuclear entry.
Despite the revelation of the biochemical properties of MEQ, whether
MEQ transforms cells and how it would exert this action remain
undefined. The present report begins to address these
questions. As there is no efficient chicken in vitro T-cell
transformation system available, we followed the approaches
successfully applied to other herpesviruses, such as
Epstein-Barr virus (EBV). In the EBV-transformed cell lines,
nine proteins and two small nuclear RNAs are expressed during latency.
Among those latent proteins at least five of them, namely, EBNA-LP, -2, -3A, and -3C and LMP1, have been implicated in cell
immortalization and/or transformation (10, 14, 21, 28, 48).
Some of them were initially identified as oncogenes based on their
ability to transform rodent fibroblast cell lines (50). The
transformed cell lines were useful in further defining the mechanisms
of action of the oncogenes.
In this report, we demonstrate that MEQ proteins are expressed
ubiquitously and abundantly in MDV tumor cell lines. Overexpression of
MEQ alone leads to transformation of Rat-2 cells, based on morphological characteristics, anchorage-independent growth, and serum-independent growth. Furthermore, MEQ protects the transformed cells from apoptosis induced by a variety of modes including tumor necrosis factor alpha, (TNF-
), C2-ceramide, UV irradiation, and serum withdrawal. Consistent with the antiapoptotic effect are the
transcriptional induction of bcl-2 and suppression of
bax, presumably induced by MEQ in those cells.
 |
MATERIALS AND METHODS |
Cells.
Rat-2 cells were maintained in Dulbecco modified
Eagle medium (DMEM [high glucose]) supplemented with 10% calf serum.
Chicken embryo fibroblasts (CEF) and duck embryo fibroblasts (DEF) were maintained in medium 199-DMEM (1:1) supplemented with 2% chicken serum
and 5% calf serum. RP1 (31), RP4 (32), RP19
(34), MSB-1 (1), RP9 (35), RP13
(33), and CU cell lines (6, 42) were maintained
as previously described.
Antibodies.
MEQ antisera (27) were used at a
1:200 dilution for immunofluorescence staining and at a 1:4,000
dilution for Western blotting, and antibromodeoxyuridine (BrdU)
monoclonal antibody (MAb) (Amersham) was used undiluted.
Western blotting.
Total cell lysates were prepared in lysis
buffer at 10 × 106 to 25 × 106
cells/ml. Cell lysates approximately equivalent to 0.5 × 106 to 1 × 106 cells were loaded in each
lane for sodium dodecyl sulfate-10% polyacrylamide gel
electrophoresis (SDS-10% PAGE). The gels were then transferred to
Immobilon polyvinylidene difluoride membranes (Millipore). The
membranes were then blocked with 5% bovine serum albumin
(BSA)-phosphate-buffered saline containing 0.1% Tween 20 (PBST). The
Western blotting was performed as previously described (19).
Briefly, the blots were incubated with primary antibodies in PBST for
1 h, washed three times, and followed by incubation with alkaline
phosphatase-conjugated secondary antibodies for 1 h, washed three
times, and then exposed to substrates (BCIP [5-bromo-4-chloro-3-indolylphosphate] and Nitro Blue Tetrazolium). The Tropix Western-Light chemiluminescent detection system was employed
to analyze Bcl-2 and Bax blots. The procedures were performed as
described by the manufacturer.
Transforming assays.
Anchorage-independent growth was
measured by soft agar colony assay to evaluate transforming potential.
Briefly, this assay was performed in six-well plates with a base of 2 ml of medium containing 4% fetal bovine serum with 0.5% Noble agar
(Difco). Cells were seeded in 2 ml of medium containing 4% fetal
bovine serum with 0.35% agar at 104 cells/ml and layered
onto the base. The number of colonies was scored under a microscope
after 3 to 4 weeks.
Apoptotic assays.
Cells were treated with different
apoptosis-promoting vehicles, including serum withdrawal (3 days),
mouse TNF-
(mTNF-
) (1 ng/ml) plus serum withdrawal (24 h),
C2-ceramide (10 µM) plus serum withdrawal (12 h), UV irradiation (50 J/m2, 24 h), and cycloheximide (CHX) (24 h). Apoptosis
was evaluated by two different assays. First, a terminal
deoxynucleotidyl transferase (TdT) assay was performed with the ApopTag
in situ apoptosis detection kit (Oncor) according to the
manufacturer's specifications. Second, DAPI
(4',6-diamidino-2-phenylindole) staining was performed to examine the
chromosomal pattern as described by Liu et al. (27).
BrdU incorporation assay.
DNA synthesis activity can be
monitored by incorporation of BrdU. Briefly, cells were grown on
coverslips inside the six-well plates. Serum deprivation was imposed
for 3 days before BrdU (Amersham) was added to the media for 12 h.
Cells were fixed with 1% formaldehyde in phosphate-buffered saline
(PBS) for 20 min, washed with PBS and treated with 1 N HCl for 10 min,
washed, blocked with 3% BSA-PBS for 1 h, and stained with
anti-BrdU MAb (Amersham) for 1 h at 37°C followed by fluorescein
isothiocyanate-conjugated anti-mouse immunoglobulin Gs for 1 h at
room temperature.
Indirect immunofluorescence.
Immunofluorescence staining was
performed as previously described (27) with some
modifications. Briefly, cells were seeded at 5 × 105/well in six-well plates with coverslips inside. Media
were aspirated, and the cells were washed with PBS twice before the
cells were fixed with 3.7% formaldehyde-PBS for 20 min. After another
PBS wash, the cells were permeabilized with 0.1% Triton X-100 in PBS for 5 min followed by blocking with 3% BSA-PBST for 1 h. Cells were then incubated with primary antibodies for 1 h. After two washes with PBST, the secondary antibodies conjugated with fluorescein isothyocyanate or Texas red (Vector Labs) were applied for another hour, and the cells were examined under a fluorescence microscope (40×
objective; Nikon).
Reverse transcriptase-polymerase chain reaction (RT-PCR).
Total cell RNA was isolated from cells with TRIzol reagent (Life
Technologies). Reverse transcription was then achieved with a
Boehringer Mannheim reverse transcription kit. Primers for
meq (5' sequence, GCCATGGCTCAGGAGCCAGAGCCG;
3' sequence, GGGAATTCTATATAACTAGGGGAGAA), bcl-2 (5' sequence, AACCATGGCGCACGCTGGGAGA;
3' sequence, GAATTCACTTGTGGCCCAGATA), bax
(5' sequence, CCTCGAGCCATGGACGGGTCCGGGGAGCAGCTTGGGAGC;
3' sequence, CAGATCTCAGCCCATCTT), and the gene for
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (5' sequence,
CGGAGTCAACGGATTTGGTCGTAT; 3' sequence, AGCCTTCTCCATGGTGGTGAAGAC) were used in subsequent PCR to detect the transcriptional level of these genes. Only 16 cycles were programmed for amplification to avoid overamplification of the transcripts in lower abundance.
 |
RESULTS |
MEQ proteins are abundantly expressed in MDV cell lines.
Although meq transcripts have been detected persistently in
the MDV tumor samples and in the cell lines, MEQ's expression at the
protein level has not been addressed due to the lack of avid
antibodies. Recently, we generated rabbit antisera against bacterially
expressed MEQ (first 168 amino acids) proteins (27). The
results of Western blotting are consistent with the expression data
based on Northern blots published previously (19). Briefly, MEQ is highly expressed in all MDV tumor cell lines, such as RP1, RP4,
RP19, and MSB1, as well as MDV-infected T-cell lines CU14 and CU41.
However, MEQ is not detectable in normal CEF, DEF, or other cell lines
derived from reticuloendotheliosis virus or avian leukosis virus
transformation, including CU205, CU91, RP9, and RP13 (Fig.
1A). MEQ protein migrates in denaturing
gel as a broad band whose molecular mass ranges between 50 and 75 kDa,
and the mean size varies among different cell lines, presumably due to posttranslational modifications and a disorderly proline-rich structure. Recent findings of alternatively spliced MEQ products (26, 37) and the existence of rearranged genome in some cell lines (26) should also contribute to the variations in MEQ
sizes.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 1.
Constitutive expression of MEQ proteins in the MDV tumor
cell lines and MEQ-transformed Rat-2 cells. Total cell lysates were
prepared from MDV cell lines (RP1, RP4, RP19, and MSB1), MDV-infected
T-cell lines (CU14 and CU41), reticuloendotheliosis virus cell lines
(CU91, CU205, and RP13), avian leukosis virus cell line (RP9), and
normal avian embryo fibroblasts (CEF and DEF) (A) as well as from
MEQ-transformed and vector-infected Rat-2 cells (B). Cell lysates
equivalent to approximately 0.5 × 106 to 1 × 106 cells per lane were analyzed by SDS-10% PAGE. The
gels were transferred to Immobilon polyvinylidene difluoride membranes
and blotted with MEQ antisera (1:4,000 dilution). The Western blots
were subsequently detected with the conventional alkaline phosphatase
method.
|
|
MEQ is capable of transforming a rodent fibroblast cell line Rat-2
when overexpressed.
As described before, several lines of evidence
suggest that MEQ may play a role in oncogenesis. First, MEQ's
structure is similar to those of the Jun/Fos oncoproteins and
expression of MEQ is heightened in T-cell lymphomas but not in
chronically infected cells (19, 47). Second, recent
observations have demonstrated that MEQ antisense transcripts reversed
the transformed phenotype of MSB1 (52). However, due to the
lack of an efficient chicken T-cell transformation system, it is
presently not possible to directly demonstrate the oncogenicity of MEQ
in its natural target cells. We therefore utilized Rat-2 fibroblast
transformation assays. For this experiment we first introduced
meq into the murine retroviral vector pBabe-puro
(30) and transfected the resulting construct, pBabe-MEQ,
into a packaging cell line,
2. The viral supernatants were then
collected and used to infect Rat-2 cells. After selection with
puromycin, the positive clones were pooled to avoid clonal variations
that might complicate the interpretation of the results. Several
passages later, the MEQ-infected Rat-2 cells became morphologically transformed; they are round to deformed and nonrefractile (Fig. 2B), as opposed to being spindle-shaped
and refractile, like the untransformed vector-infected Rat-2 cells
(Fig. 2A). In addition, they were devoid of contact inhibition, and
numerous heaped-up foci could be observed. Moreover, they became
resistant to trypsinization, presumably due to altered expressions of
extracellular matrix proteins, and produced huge colonies in soft agar
(Fig. 2D). Our indirect immunofluorescence staining (27) and
Western blotting (Fig. 1B) showed that MEQ is expressed in these cells
at a moderate to high level. Interestingly, three discrete bands were
detected by MEQ antisera in pBabe-MEQ-transformed cells as opposed to
the broad diffuse band found in all MDV cell lines as shown in Fig. 1A.
The less complicated pattern is in part attributed to the inability of
MEQ cDNA to undergo alternative splicing. Taken together, these results
provide the first direct evidence that unspliced meq behaves
like an oncogene and can transform Rat-2 cells, when overexpressed.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 2.
Transformation of Rat-2 cells by MEQ. Rat-2 cells were
infected with supernatants containing viruses derived from either
pBabe-puro vector or pBabe-MEQ construct. The transforming potential of
MEQ was evaluated by morphology (A and B) and soft agar colony assay (C
and D). Magnification, ×55.
|
|
MEQ promotes serum-independent growth of MEQ-transformed Rat-2
cells.
In addition to the morphological transformation described
above, MEQ-transformed Rat-2 cells continued to proliferate in the absence of serum (Fig. 3). This
observation was validated with further experiments using BrdU
incorporation (to measure DNA synthesis) and DAPI staining (to analyze
chromosomal structure). As shown in Fig.
4C', after serum withdrawal for 3 days,
more than 75% of MEQ-transformed Rat-2 cells showed signs of BrdU
incorporation and showed mitotic figures as revealed by DAPI staining
(Fig. 4B). In contrast, the vector-infected Rat-2 cells underwent
either growth arrest (with very little BrdU incorporation) (Fig. 4A') or apoptosis (Fig. 4A). Apoptosis was confirmed by TdT
assay with the ApopTag in situ apoptosis detection kit
(Fig. 4C, C', D and D'). These findings suggest that MEQ-transformed
Rat-2 cells either can synthesize their own growth factors
through an autocrine loop or may bypass the need of growth factor
stimulation through constitutive activation of mitogenic pathways
downstream of growth factor receptors. Similar scenarios are often
found in the cases for transcription factor-derived oncogenes such as
Jun and Fos (2, 11).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
MEQ-induced serum-independent growth in MEQ-transformed
Rat-2 cells. A total of 2 × 105 MEQ-transformed and
the same number of vector-infected Rat-2 cells were cultured in the
absence of serum for up to 4 days. The cell number was counted at
24 h intervals, in duplicate.
|
|

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 4.
MEQ-mediated BrdU incorporation and inhibition of
apoptosis in serum-starved MEQ-transformed Rat-2 cells.
BrdU was added to the media of MEQ-transformed and vector-infected
Rat-2 cells for 12 h after cells were serum starved for 3 days.
Cells were then fixed and stained with anti-BrdU MAb (A' and B') and
counterstained with DAPI (A and B). Meanwhile, a TdT assay was used to
evaluate apoptosis. Briefly, MEQ-transformed and
vector-infected Rat-2 cells were also serum starved for 3 days, fixed
and stained with ApopTag (C' and D') and counterstained with DAPI (C
and D). Magnification, ×216.
|
|
MEQ displays antiapoptotic potential.
Oncogenic
herpesviruses generally encode separate gene products to induce host
cell immortalization and/or transformation as well as to block
apoptosis (see Discussion). In some cases, however, both
properties can be derived from the same viral gene products, such as
LMP1 (16, 21).
The above-described experiments implicate MEQ in the abrogation of
serum withdrawal-induced apoptosis of Rat-2 cells. We
then
asked whether MEQ is antiapoptotic. Rat-2 cells and
their MEQ-transformed
counterparts were treated with a number of
reagents in addition
to being subjected to serum withdrawal. The
hallmarks of apoptosis
include (i) the formation of
distinct ladders of nucleosomal DNA
fragments (180 to 200 bp), which
can be analyzed by DNA fragmentation
or TdT assays, (ii) chromosomal
condensation and/or nuclear membrane
breakdown, and (iii)
formation of apoptotic bodies, which can
be evaluated
by DAPI staining. The antiapoptotic effects of MEQ
were
measured as described above.
Serum withdrawal.
As shown in Fig.
5A and B, in the presence of serum, 0 to
10% of cells are apoptotic in both vector-infected and
MEQ-transformed Rat-2 cells. Upon serum withdrawal for 3 days, 60 to
70% of the vector-infected Rat-2 cells became apoptotic
(Fig. 5E), whereas only 5 to 10% of MEQ-transformed Rat-2 cells
underwent apoptosis (Fig. 5F).

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 5.
Protection of Rat-2 cells from apoptosis by
MEQ. MEQ-transformed and vector-infected Rat-2 cells were treated with
a variety of apoptosis-inducing vehicles including serum
withdrawal, TNF- , C2-ceramide (C2), UV irradiation, and CHX.
Apoptosis was assessed with DAPI staining. Magnification, ×344.
|
|
TNF-
treatment.
Treatment with mTNF-
(1 ng/ml) under
normal serum condition did not induce apoptosis in Rat-2
(vector) cells (Fig. 5C). However, treatment with mTNF-
in the
absence of serum rapidly induced apoptosis in
vector-infected Rat-2 cells within 18 to 24 h, which represents a
significant shortening of the period required for serum withdrawal to
induce apoptosis. A total of 60 to 70% of vector-infected
Rat-2 cells became apoptotic (Fig. 5G), compared to only 5 to 10% of MEQ-transformed Rat-2 cells (Fig. 5H).
C2-ceramide treatment.
Similarly, when a downstream mediator
of the TNF-
pathway, C2-ceramide (10 µM), was administered in the
presence of serum, no apoptosis was induced in
vector-infected Rat-2 cells. Meanwhile, the apoptotic
effect of serum withdrawal could also be accelerated by C2-ceramide and
seemed to be much stronger than that of TNF-
. Apoptosis was observed
only 12 h after C2-ceramide treatment in addition to serum
withdrawal. Between 70 and 85% of vector-infected Rat-2 cells appeared
apoptotic (Fig. 5I), compared to only 0 to 5% of
MEQ-transformed Rat-2 cells (Fig. 5J).
UV irradiation.
Likewise, when cells were subjected to UV
irradiation (50 J/m2), 80 to 90% of vector-infected Rat-2
cells underwent apoptosis 24 h later (Fig. 5K);
conversely, only 10 to 20% of MEQ-transformed Rat-2 cells were found
to be apoptotic (Fig. 5L).
CHX treatment.
Interestingly, the blocking of TNF-
-induced
apoptosis by MEQ apparently requires protein synthesis, as
the addition of the protein synthesis inhibitor CHX reduces this block.
MEQ did not appear to efficiently block apoptosis induced
by CHX (5 µg/ml, 24 h) (Fig. 5N), especially in the presence of
TNF-
(Fig. 5P). Under these conditions, there seemed to be more
apoptotic cells in MEQ-transformed Rat-2 cells (Fig. 5P)
than in vector-infected Rat-2 cells (Fig. 5O). This, however, is due to
the fact that most of vector-infected Rat-2 cells treated with CHX
and TNF-
underwent apoptosis and were already detached
from the petri dish within 12 h.
In summary (Fig.
6), our data strongly
suggest that MEQ is capable of antagonizing apoptosis
mediated through TNF-

pathways
(TNF-

and C2-ceramide treatments),
UV irradiation, and serum
withdrawal. This antiapoptotic
process requires new protein synthesis
and is consistent with MEQ being
a transcription factor that induces
the expression of genes involved in
apoptosis, a notion that is
supported by experiments
described in the following section.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 6.
Statistical analysis of MEQ-mediated inhibition of
apoptosis. The percent apoptotic cells was
calculated based on the results shown in Fig. 5. C2, C2-ceramide.
|
|
MEQ up-regulates bcl-2 expression and down-regulates
bax expression.
Since MEQ is a transcription factor
(39) whose subcellular localization is primarily in the
nucleus/nucleolus (27), we postulate that the
antiapoptotic effect is likely mediated through regulation
of genes involved in apoptosis and/or cell survival at the
transcriptional level. Among these, bcl-2 and bax
are two candidate genes that are shown to play triggering roles in cell survival and apoptosis, respectively.
As an initial step to explore the possible MEQ-regulated target genes
that antagonize apoptosis, we performed Western blotting
on
vector-infected Rat-2 cells and MEQ-transformed Rat-2 cells
to examine
the expression levels of Bcl-2 and Bax. As shown in
Fig.
7A (lane 3), vector-infected Rat-2 cells
express a very low
level of Bcl-2 but a high level of Bax. In contrast,
MEQ-transformed
Rat-2 cells in the presence of serum (Fig.
7A, lane 1)
expressed
significantly higher levels of Bcl-2, while Bax expression
was
completely turned off. When MEQ-transformed Rat-2 cells were
treated
with C2-ceramide in the absence of serum, the level of Bcl-2
expression
was reduced but was still significantly higher than that of
vector-infected
Rat-2 cells (Fig.
7A, lane 2). Bax, on the other hand,
remains
down-regulated (Fig.
7A, lane 2). We further performed an
RT-PCR
experiment to determine whether the expression of Bcl-2 and Bax
is regulated at the transcriptional or translational level. As
shown in
Fig.
7B, the transcription of
bcl-2 is clearly enhanced,
whereas the transcription of
bax is completely down
modulated
in MEQ-transformed Rat-2 cells. We were unable to recover
enough
Rat-2 cells treated with C2-ceramide in the absence of serum to
perform either Western blotting or RT-PCR, since most of the cells
became apoptotic and detached from the plate. These
findings suggest
that MEQ directly or indirectly regulates the
expression of
bcl-2 and
bax genes at the
transcriptional level, thereby contributing
to its
antiapoptotic effects.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 7.
Induction of bcl-2 and suppression of
bax expressions in MEQ-transformed Rat-2 cells. (A) Total
cell lysates were prepared from MEQ-transformed Rat-2 cells grown in
the presence of serum (lane 1) or after treatment with C2-ceramide in
the absence of serum (lane 2) and vector-infected Rat-2 cells (in the
presence of serum) (lane 3) and analyzed by SDS-PAGE. The Western blots
were stained with rabbit anti-Bcl-2 and -Bax antisera and then detected
with a Tropix Western-Light chemiluminescent kit. (B) RT-PCR was
performed on total RNA extracted from MEQ-transformed Rat-2 cells grown
in the presence of serum (lane 1) or after treatment with C2-ceramide
in the absence of serum (lane 2). RT-PCR was similarly carried out with
vector-infected Rat-2 cells grown in the presence of serum (lane 3).
GAPDH gene expression was used as an internal control for the quality
and quantity of the RT-PCR products.
|
|
 |
DISCUSSION |
In this study we analyzed the transforming potential of MEQ, a
putative oncoprotein of MDV. We show that the meq gene
effectively transforms established Rat-2 fibroblasts but only
marginally transforms primary embryo fibroblasts (data not shown).
Thus, unlike most retroviral oncogenes, but similar to herpesviral
oncogenes, MEQ alone is not capable of transforming primary cells and
may require additional cooperating oncogenes to display its full
transforming activity (10, 14, 21, 28, 48). Nevertheless,
our data suggest that MEQ is potentially oncogenic. In our study,
injection of chickens with replication-defective virus carrying MEQ
yielded a low incidence (5%) of sarcomas, which eventually
metastasized to internal organs such as the liver, spleen, and lungs
(unpublished results), consistent with its being a weak oncogene.
Oncogenesis is a complex process involving multiple steps, and
individual oncogenes act on different steps: some override the
G1/S restriction and thus activate cell cycle progression, some affect cell-cell communication, and others prevent cell death (4, 23). In this report we show that MEQ is able to induce morphological changes and anchorage-independent growth and to protect
transformed cells from apoptosis. MEQ is a transcription factor in the family of the Jun/Fos oncoproteins. MEQ dimerizes with
Jun with great affinity and enhances its transactivation (39). We presume that some of the growth stimulation
functions may be attributed to MEQ's ability to activate the
oncoprotein Jun or other bZIP proteins. This hypothesis, however, has
yet to be experimentally demonstrated. A striking observation from this
study is that Rat-2 cells transformed by MEQ are resistant to
apoptosis induced by a variety of stimuli including
additions of C2-ceramide or TNF-
, UV irradiation, and serum (growth
factor) starvation. Some of these apoptotic regimens
utilize common signaling pathways leading to apoptosis. For
instance, it has been shown that the sphingolipid ceramide is a
downstream effector of TNF receptor (TNF-R) (15).
Administration of exogenous C2-ceramide thus effectively activates the
apoptotic pathway, bypassing the activation of TNF-R.
However, in our study, we found that neither TNF-
nor C2-ceramide
alone could induce apoptosis in Rat-2 cells. Efficient
induction of apoptosis by these agents occurred only in the
absence of serum, which contains growth factors, or in the presence of
the protein synthesis inhibitor CHX.
How does MEQ perturb the apoptotic pathway? Analysis of
Bcl-2 expression in MEQ-transformed Rat-2 cells reveals significant elevation at both protein and RNA levels. Conversely, the levels of Bax
protein and RNA are reduced. It is well documented that overexpression
of Bcl-2 in many cell types can antagonize apoptosis induced by serum deprivation, UV irradiation, TNF-
, and C2-ceramide treatments (13, 49). It is thought that Bcl-2 may prevent apoptosis through interaction with the upstream activators
(CED-4) of ICE/caspases (9, 44, 51) or by blocking the
release of cytochrome c from mitochondria (22,
53). However, the exact mechanisms remain to be elucidated. Bax,
on the other hand, is a key effector molecule in executing the
apoptotic process (36). In our studies, the
induction of bcl-2 and the suppression of bax at
the transcriptional level appear to correlate with the inhibition of
apoptosis in MEQ-transformed Rat-2 cells. It is not clear
whether this modulation is through direct binding of MEQ to the
promoter of these genes or through other factors activated by MEQ. We
note that MEQ binding sites (MERE1 and -2) are found in the promoter of
the human bcl-2 gene. Whether the same motifs are present in
the promoters of rat bcl-2 and bax genes remains to be established. It is possible that other Bcl-2- and Bax-like molecules are regulated by MEQ as well.
While an antiapoptotic property of a viral gene product may
impact its transforming potential, most herpesviruses, oncogenic or
not, have evolved a number of ways to prevent infected cells from
premature cell death during viral replication and/or latency. Several
mechanisms have been utilized by herpesviruses to dodge apoptosis of the host cells (for a review, see
reference 46). First, some herpesviruses encode
Bcl-2 homologs, such as EBV BHRF-1 (17), herpesvirus
saimiri ORF16 (43), and human herpesvirus 8 KSbcl-2
(8). These molecules presumably function to antagonize apoptosis in a manner similar to that of Bcl-2. Second,
some herpesviruses encode p53-binding proteins, such as EBV EBNA-LP
(45) and BZLF-1/ZEBRA (54). p53 is known to
trigger apoptosis at least in part by transactivating the
expression of Bax and down-modulating the expression of Bcl-2
(29). Whether these herpesviral p53-binding proteins can
inhibit apoptosis through p53 sequestration remains to be
elucidated. It is noteworthy that MEQ has been found to interact with
p53 in vitro (5). The up-regulation of Bcl-2 and
down-regulation of Bax observed in MEQ-transformed Rat-2 cells might
thus be mediated by p53 inhibition, although there is very little p53
expressed in Rat-2 and MEQ-transformed Rat-2 cells. Third, some
herpesviruses encode death effector domain-containing molecules, such
as equine herpesvirus 2 E8 protein, that interfere with signaling
transduction of Fas-TNF-R (3, 18) pathways. Last, some
herpesviruses encode transcription factors to block apoptosis, such as EBV LMP1 (16, 41), herpes
simplex virus type 1 ICP4 (25), and cytomegalovirus IE1 and
IE2 (55). LMP1 has been known to induce the expression of
Bcl-2 in B cells (16) and A20, a zinc finger protein that
can inhibit apoptosis, in epithelial cells (12).
The target genes involved in ICP4-, IE1-, and IE2-mediated protection
against apoptosis have not been identified yet. Our data
add MEQ to the growing list of antiapoptotic herpesviral gene products. While the focus of this report is on the transforming potential, MEQ may function to prolong the cell life span during MDV
replication as well.
In summary, this report provides the first investigation of the
biological properties of MEQ, and MDV gene product implicated in
oncogenic and latent processes of MDV. MEQ has been well delineated as
a transcription factor with the characteristics of nuclear localization, dimerization, transactivation and/or repression, and
DNA-binding activity. Here, it is shown that MEQ is mitogenic and
antiapoptotic. The former is reflected by its ability to
increase growth rate, induce BrdU incorporation, and elicit
serum-independent growth. The latter is manifested by its potential to
protect cells from apoptosis induced by serum starvation
and by treatments with a number of apoptosis-inducing
reagents. Our studies provide a framework to understand the mechanisms
of MEQ as an effector in MDV oncogenesis.
 |
ACKNOWLEDGMENTS |
We thank K. A. Schat for CU cell lines and J. P. Morgenstern for the pBabe vector. We also thank K. Everiss and A. W. Grasso for critical reading of the manuscript.
This work was supported by grants from the USDA (93-37204-9340 to
L.F.L. and H.-J.K.), the NCI (CA46613 to H.-J.K.), and the Council for
Tobacco Research (4034 to H.-J.K.). J.-L.L. is a recipient of a USDA
fellowship.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Dept. of
Molecular Biology and Microbiology, School of Medicine, Case Western
Reserve University, Cleveland, OH 44106-4960. Phone: (216) 368-6655. Fax: (216) 368-3055. E-mail: hxk5{at}po.cwru.edu.
 |
REFERENCES |
| 1.
|
Akiyama, Y., and S. Kato.
1974.
Two cell lines from lymphomas of Marek's disease.
Biken J.
17:105-116[Medline].
|
| 2.
|
Angel, P., and M. Karin.
1991.
The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation.
Biochim. Biophys. Acta
1072:129-157[Medline].
|
| 3.
|
Bertin, J.,
R. C. Armstrong,
S. Ottilie,
D. A. Martin,
Y. Wang,
S. Banks,
G.-H. Wang,
T. G. Senkenvich,
E. S. Alnemri,
B. Moss,
M. J. Lenardo,
K. J. Tomaselli, and J. I. Cohen.
1997.
Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR-induced apoptosis.
Proc. Natl. Acad. Sci. USA
94:1172-1176[Abstract/Free Full Text].
|
| 4.
|
Bishop, J. M.
1991.
Molecular themes in oncogenesis.
Cell
64:235-248[Medline].
|
| 5.
| Brunovskis, P. 1997. Personal communication.
|
| 6.
|
Calnek, B. W.,
W. R. Shek, and K. A. Schat.
1981.
Spontaneous and induced herpesvirus genome expression in Marek's disease tumor cell lines.
Infect. Immun.
34:483-491[Abstract/Free Full Text].
|
| 7.
|
Calnek, B. W.
1985.
Marek's disease a model for herpesvirus oncology.
Crit. Rev. Microbiol.
12:293-320.
|
| 8.
|
Cheng, E. H.,
J. Nickolas,
D. S. Bellows,
G. S. Hayward,
H. G. Guo,
M. S. Reitz, and J. M. Hardwick.
1997.
A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak.
Proc. Natl. Acad. Sci. USA
94:690-694[Abstract/Free Full Text].
|
| 9.
|
Chinnaiyan, A. M.,
K. O'Rourke,
B. R. Lane, and V. M. Dixit.
1997.
Interactions of CED-4 with CED-3 and CED-9: a molecular framework for cell death.
Science
275:1122-1126[Abstract/Free Full Text].
|
| 10.
|
Cohen, J. I.,
F. Wang,
J. Mannick, and E. Kieff.
1989.
Epstein-Barr virus nuclear protein 2 is a key determinant of B lymphocyte transformation.
Proc. Natl. Acad. Sci. USA
86:9558-9562[Abstract/Free Full Text].
|
| 11.
|
Curran, T., and P. K. Vogt.
1992.
Dangerous liaisons: Fos and Jun, oncogenic transcription factors, p. 797-836. In
S. L. McNight, and K. Yamamota (ed.), Transcription regulation.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 12.
|
Fries, K. L.,
W. E. Miller, and N. Raab-Traub.
1996.
Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene.
J. Virol.
70:8653-8659[Abstract].
|
| 13.
|
Hale, A. J.,
C. A. Smith,
L. C. Sutherland,
V. E. A. Stoneman,
V. L. Longthorne,
A. C. Culhane, and G. T. Williams.
1996.
Apoptosis: molecular regulation of cell death.
Eur. J. Biochem.
236:1-26[Medline].
|
| 14.
|
Hammerschmidt, W., and B. Sugden.
1989.
Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes.
Nature (London)
340:393-397[Medline].
|
| 15.
|
Hannun, Y. A., and L. M. Obeid.
1995.
Ceramide: an intracellular signal for apoptosis.
Trends Biochem. Sci.
20:73-77[Medline].
|
| 16.
|
Henderson, S.,
M. Rowe,
C. Gregory,
C. D. Croom,
F. Wang,
R. Longnecker,
E. Kieff, and A. Rickinson.
1991.
Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death.
Cell
65:1107-1115[Medline].
|
| 17.
|
Henderson, S.,
D. Huen,
M. Rowe,
C. Dawson,
G. Johnson, and A. Rickinson.
1993.
Epstein-Barr virus-encoded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death.
Proc. Natl. Acad. Sci. USA
90:8479-8483[Abstract/Free Full Text].
|
| 18.
|
Hu, S.,
C. Vincenz,
M. Buller, and V. M. Dixit.
1997.
A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis.
J. Biol. Chem.
272:9621-9624[Abstract/Free Full Text].
|
| 19.
|
Jones, D.,
L. Lee,
J.-L. Liu,
H.-J. Kung, and J. K. Tillotson.
1992.
Marek disease virus encodes a basic-leucine zipper gene resembling the fos/jun oncogenes that is highly expressed in lymphoblastoid tumors.
Proc. Natl. Acad. Sci. USA
89:4042-4046[Abstract/Free Full Text].
|
| 20.
|
Kato, S., and K. Hirai.
1985.
Marek's disease virus.
Adv. Virus Res.
30:225-277[Medline].
|
| 21.
|
Kaye, K. M.,
K. M. Izumi, and E. Kieff.
1993.
Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation.
Proc. Natl. Acad. Sci. USA
90:9150-9154[Abstract/Free Full Text].
|
| 22.
|
Kluck, R. M.,
E. Bossy-Wetzel,
D. R. Green, and D. D. Newmeyer.
1997.
The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis.
Science
275:1132-1136[Abstract/Free Full Text].
|
| 23.
|
Kung, H.-J., and J.-L. Liu.
1997.
Retroviral oncogenesis, p. 235-266. In
N. Nathanson, et al. (ed.), Viral pathogenesis.
Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 24.
|
Kung, H.-J.,
A. Tanaka, and M. Nonoyama.
1995.
Two gene families of Marek's disease virus with a potential role in tumor induction in chicken.
Int. J. Oncol.
6:997-1002.
|
| 25.
|
Leopardi, R., and B. Roizman.
1996.
The herpes simplex virus major regulatory protein ICP4 blocks apoptosis induced by the virus or by hyperthermia.
Proc. Natl. Acad. Sci. USA
93:9538-9587.
|
| 26.
| Li, D. Unpublished results.
|
| 27.
|
Liu, J.-L.,
L. F. Lee,
Y. Ye,
Z. Qian, and H.-J. Kung.
1997.
Nucleolar and nuclear localization properties of a herpesvirus bZIP oncoprotein, MEQ.
J. Virol.
71:3188-3196[Abstract].
|
| 28.
|
Mannick, J. B.,
J. I. Cohen,
M. Birkenbach,
A. Marchini, and E. Kieff.
1991.
The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation.
J. Virol.
65:6826-6837[Abstract/Free Full Text].
|
| 29.
|
Miyashita, T.,
S. Krajewski,
M. Kraikjeski,
H. G. Wang,
H. K. Lin,
D. A. Liebermann,
B. Hoffman, and J. C. Reed.
1994.
Tumor-suppressor p53 is a regulator of bcl-2 and bax gene-expression in vitro and in vivo.
Oncogene
9:1799-1805[Medline].
|
| 30.
|
Morgenstern, J. P., and H. Land.
1990.
Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper packaging cell line.
Nucleic Acids Res.
18:3587-3596[Abstract/Free Full Text].
|
| 31.
|
Nazerian, K.,
E. A. Stephens,
J. M. Sharma,
L. F. Lee,
M. Gailitis, and R. L. Witter.
1977.
A nonproducer T lymphoblastoid cell line from Marek's disease transplantable tumor (JMV).
Avian Dis.
21:69-76[Medline].
|
| 32.
|
Nazerian, K.,
W. Payne,
L. F. Lee, and R. L. Witter.
1978.
Marek's disease virus (MDV) transformed lymphoblastoid cell line in a syngeneic system, abstr. S373, p. 274.
Abstracts of the 78th Annual Meeting of the American Society for Microbiology 1978.
American Society for Microbiology, Washington, D.C.
|
| 33.
|
Nazerian, K.,
R. L. Witter,
L. B. Crittenden,
M. R. Noori-Dalloii, and H.-J. Kung.
1982.
An IgM-producing B lymphoblastoid cell line established from lymphomas induced by a non-defective reticuloendotheliosis virus.
J. Gen. Virol.
58:351-360[Abstract/Free Full Text].
|
| 34.
|
Nazerian, K.,
A. K. Elmubarak, and J. M. Sharama.
1982.
Establishment of B-lymphoblastoid cell lines from Marek's disease virus-induced tumors in turkeys.
Int. J. Cancer
29:63-68[Medline].
|
| 35.
|
Okazaki, W.,
R. L. Witter,
C. Romero,
K. Nazerian,
J. M. Sharama,
A. Fadly, and D. Ewert.
1980.
Induction of lymphoid leukosis transplantable tumors and the establishment of lymphoblastoid cell lines.
Avian Pathol.
9:311-329.
[Medline] |
| 36.
|
Oltvai, Z. N.,
C. L. Milliman, and S. J. Korsmeyer.
1993.
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.
Cell
74:609-619[Medline].
|
| 37.
|
Peng, Q.,
M. Zeng,
Z. A. Bhuiyan,
E. Ubakata,
A. Tanaka,
M. Nonoyama, and Y. Shirazi.
1995.
Isolation and characterization of Marek's disease virus (MDV) cDNAs mapping to the Bam HI-I2, BamHI-Q2, and BamHI-L fragments of the MDV genome form lymphoblastoid cells transformed and persistently infected with MDV.
Virology
213:590-599[Medline].
|
| 38.
|
Powell, P. C.
1985.
Marek's disease virus in the chicken.
Adv. Viral Oncol.
5:103-127.
|
| 39.
|
Qian, Z.,
P. Brunovskis,
F. Rauscher III,
L. Lee, and H.-J. Kung.
1995.
Transactivation activity of Meq, a Marek's disease herpesvirus bZIP protein persistently expressed in latently infected transformed T cells.
J. Virol.
69:4037-4044[Abstract].
|
| 40.
|
Qian, Z.,
P. Brunovskis,
L. Lee,
P. K. Vogt, and H.-J. Kung.
1996.
Novel DNA binding specificities of a putative herpesvirus bZIP oncoprotein.
J. Virol.
70:7161-7170[Abstract/Free Full Text].
|
| 41.
|
Rowe, M.,
M. Peng-Pilon,
D. S. Huen,
R. Hardy,
D. Croom-Carter,
E. Lundgren, and A. B. Rickinson.
1994.
Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF- B activation and to induction of cell surface markers.
J. Virol.
68:5602-5612[Abstract/Free Full Text].
|
| 42.
|
Schat, K. A.,
W. D. Pratt,
R. Morgan,
D. Weinstock, and B. W. Calnek.
1992.
Stable transfection of reticuloendotheliosis virus-transformed lymphoblastoid cell lines.
Avian Dis.
36:432-439[Medline].
|
| 43.
|
Smith, C. A.
1995.
A novel viral homologue of Bcl-2 and Ced-9.
Trends Cell Biol.
5:344.
[Medline] |
| 44.
|
Spector, M. S.,
S. Desnoyers,
D. J. Hoeppner, and M. O. Hengartner.
1997.
Interaction between the C. elegans cell-death regulators CED-9 and CED-4.
Nature (London)
385:653-656[Medline].
|
| 45.
|
Szekely, L.,
G. Selivanova,
K. P. Magnusson,
G. Klein, and K. G. Wiman.
1993.
EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins.
Proc. Natl. Acad. Sci. USA
90:5455-5459[Abstract/Free Full Text].
|
| 46.
|
Teodoro, J. G., and P. E. Branton.
1997.
Regulation of apoptosis by viral gene products.
J. Virol.
71:1739-1746[Medline].
|
| 47.
|
Tillotson, J. K.,
H.-J. Kung, and L. F. Lee.
1988.
Accumulation of viral transcripts coding for a DNA binding protein in Marek's disease tumor cells, p. 128-134.
The 3rd International Symposium on Marek's Disease.
Japanese Association on Marek's Disease, Osaka, Japan.
|
| 48.
|
Tomkinson, B.,
E. Robertson, and E. Kieff.
1993.
Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation.
J. Virol.
67:2014-2025[Abstract/Free Full Text].
|
| 49.
|
Vaux, D. L., and A. Strasser.
1996.
The molecular biology of apoptosis.
Proc. Natl. Acad. Sci. USA
93:2239-2244[Abstract/Free Full Text].
|
| 50.
|
Wang, D.,
D. Liebowitz, and E. Kieff.
1985.
An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells.
Cell
43:831-840[Medline].
|
| 51.
|
Wu, D.,
H. D. Wallen, and G. Nunez.
1997.
Interaction and regulation of subcellular localization of CED-4 by CED-9.
Science
275:1126-1129[Abstract/Free Full Text].
|
| 52.
|
Xie, Q.,
A. S. Anderson, and R. W. Morgan.
1996.
Marek's disease virus (MDV) ICP4, pp38, and meq genes are involved in the maintenance of transformation of MDCC-MSB1 MDV-transformed lymphoblastoid cells.
J. Virol.
70:1125-1131[Abstract].
|
| 53.
|
Yang, J.,
X. Liu,
K. Bhalla,
C. N. Kim,
A. M. Ibrado,
J. Cai,
T.-I. Peng,
D. P. Jones, and X. Wang.
1997.
Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked.
Science
275:1129-1132[Abstract/Free Full Text].
|
| 54.
|
Zhang, Q.,
D. Gutsch, and S. Kenney.
1994.
Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency.
Mol. Cell. Biol.
14:1929-1938[Abstract/Free Full Text].
|
| 55.
|
Zhu, H.,
Y. Shen, and T. Shenk.
1995.
Human cytomegalovirus IE1 and IE2 proteins block apoptosis.
J. Virol.
69:7960-7970[Abstract].
|
J Virol, January 1998, p. 388-395, Vol. 72, No. 1
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Suchodolski, P. F., Izumiya, Y., Lupiani, B., Ajithdoss, D. K., Gilad, O., Lee, L. F., Kung, H.-J., Reddy, S. M.
(2009). Homodimerization of Marek's Disease Virus-Encoded Meq Protein Is Not Sufficient for Transformation of Lymphocytes in Chickens. J. Virol.
83: 859-869
[Abstract]
[Full Text]
-
Morgan, R., Anderson, A., Bernberg, E., Kamboj, S., Huang, E., Lagasse, G., Isaacs, G., Parcells, M., Meyers, B. C., Green, P. J., Burnside, J.
(2008). Sequence Conservation and Differential Expression of Marek's Disease Virus MicroRNAs. J. Virol.
82: 12213-12220
[Abstract]
[Full Text]
-
Jarosinski, K. W., Margulis, N. G., Kamil, J. P., Spatz, S. J., Nair, V. K., Osterrieder, N.
(2007). Horizontal Transmission of Marek's Disease Virus Requires US2, the UL13 Protein Kinase, and gC. J. Virol.
81: 10575-10587
[Abstract]
[Full Text]
-
Murata, S., Chang, K.-S., Lee, S.-I., Konnai, S., Onuma, M., Ohashi, K.
(2007). Development of a nested polymerase chain reaction method to detect oncogenic Marek's disease virus from feather tips. jvdi
19: 471-478
[Abstract]
[Full Text]
-
Okada, T., Takagi, M., Murata, S., Onuma, M., Ohashi, K.
(2007). Identification and characterization of a novel spliced form of the meq transcript in lymphoblastoid cell lines derived from Marek's disease tumours. J. Gen. Virol.
88: 2111-2120
[Abstract]
[Full Text]
-
Burnside, J., Bernberg, E., Anderson, A., Lu, C., Meyers, B. C., Green, P. J., Jain, N., Isaacs, G., Morgan, R. W.
(2006). Marek's Disease Virus Encodes MicroRNAs That Map to meq and the Latency-Associated Transcript.. J. Virol.
80: 8778-8786
[Abstract]
[Full Text]
-
Trapp, S., Parcells, M. S., Kamil, J. P., Schumacher, D., Tischer, B. K., Kumar, P. M., Nair, V. K., Osterrieder, N.
(2006). A virus-encoded telomerase RNA promotes malignant T cell lymphomagenesis. JEM
203: 1307-1317
[Abstract]
[Full Text]
-
Murata, K., Hayashibara, T., Sugahara, K., Uemura, A., Yamaguchi, T., Harasawa, H., Hasegawa, H., Tsuruda, K., Okazaki, T., Koji, T., Miyanishi, T., Yamada, Y., Kamihira, S.
(2006). A Novel Alternative Splicing Isoform of Human T-Cell Leukemia Virus Type 1 bZIP Factor (HBZ-SI) Targets Distinct Subnuclear Localization. J. Virol.
80: 2495-2505
[Abstract]
[Full Text]
-
Anobile, J. M., Arumugaswami, V., Downs, D., Czymmek, K., Parcells, M., Schmidt, C. J.
(2006). Nuclear Localization and Dynamic Properties of the Marek's Disease Virus Oncogene Products Meq and Meq/vIL8. J. Virol.
80: 1160-1166
[Abstract]
[Full Text]
-
Levy, A. M., Gilad, O., Xia, L., Izumiya, Y., Choi, J., Tsalenko, A., Yakhini, Z., Witter, R., Lee, L., Cardona, C. J., Kung, H.-J.
(2005). Marek's disease virus Meq transforms chicken cells via the v-Jun transcriptional cascade: A converging transforming pathway for avian oncoviruses. Proc. Natl. Acad. Sci. USA
102: 14831-14836
[Abstract]
[Full Text]
-
Jarosinski, K. W., Osterrieder, N., Nair, V. K., Schat, K. A.
(2005). Attenuation of Marek's Disease Virus by Deletion of Open Reading Frame RLORF4 but Not RLORF5a. J. Virol.
79: 11647-11659
[Abstract]
[Full Text]
-
Liu, J.-L., Sheng, X., Hortobagyi, Z. K., Mao, Z., Gallick, G. E., Yung, W. K. A.
(2005). Nuclear PTEN-Mediated Growth Suppression Is Independent of Akt Down-Regulation. Mol. Cell. Biol.
25: 6211-6224
[Abstract]
[Full Text]
-
Lupiani, B., Lee, L. F., Cui, X., Gimeno, I., Anderson, A., Morgan, R. W., Silva, R. F., Witter, R. L., Kung, H.-J., Reddy, S. M.
(2004). Marek's disease virus-encoded Meq gene is involved in transformation of lymphocytes but is dispensable for replication. Proc. Natl. Acad. Sci. USA
101: 11815-11820
[Abstract]
[Full Text]
-
Levy, A. M., Izumiya, Y., Brunovskis, P., Xia, L., Parcells, M. S., Reddy, S. M., Lee, L., Chen, H.-W., Kung, H.-J.
(2003). Characterization of the Chromosomal Binding Sites and Dimerization Partners of the Viral Oncoprotein Meq in Marek's Disease Virus-Transformed T Cells. J. Virol.
77: 12841-12851
[Abstract]
[Full Text]
-
Gaudray, G., Gachon, F., Basbous, J., Biard-Piechaczyk, M., Devaux, C., Mesnard, J.-M.
(2002). The Complementary Strand of the Human T-Cell Leukemia Virus Type 1 RNA Genome Encodes a bZIP Transcription Factor That Down-Regulates Viral Transcription. J. Virol.
76: 12813-12822
[Abstract]
[Full Text]
-
Le Rouzic, E, Thoraval, P, Afanassieff, M, Cherel, Y, Dambrine, G, Perbal, B
(2002). Alterations of the MDV oncogenic regions in an MDV transformed lymphoblastoid cell line. Mol. Pathol.
55: 262-272
[Abstract]
[Full Text]
-
Hay, S., Kannourakis, G.
(2002). A time to kill: viral manipulation of the cell death program. J. Gen. Virol.
83: 1547-1564
[Abstract]
[Full Text]
-
Kingham, B. F., Zelnik, V., Kopácek, J., Majerciak, V., Ney, E., Schmidt, C. J.
(2001). The genome of herpesvirus of turkeys: comparative analysis with Marek's disease viruses. J. Gen. Virol.
82: 1123-1135
[Abstract]
[Full Text]
-
Endoh, D., Cho, K.-O., Tsukamoto, K., Morimura, T., Kon, Y., Hayashi, M.
(2000). Application of Representational Difference Analysis to Genomic Fragments of Marek's Disease Virus. J. Clin. Microbiol.
38: 4310-4314
[Abstract]
[Full Text]
-
Yamaguchi, T., Kaplan, S. L., Wakenell, P., Schat, K. A.
(2000). Transactivation of Latent Marek's Disease Herpesvirus Genes in QT35, a Quail Fibroblast Cell Line, by Herpesvirus of Turkeys. J. Virol.
74: 10176-10186
[Abstract]
[Full Text]
-
Tulman, E. R., Afonso, C. L., Lu, Z., Zsak, L., Rock, D. L., Kutish, G. F.
(2000). The Genome of a Very Virulent Marek's Disease Virus. J. Virol.
74: 7980-7988
[Abstract]
[Full Text]
-
Lee, L. F., Wu, P., Sui, D., Ren, D., Kamil, J., Kung, H. J., Witter, R. L.
(2000). The complete unique long sequence and the overall genomic organization of the GA strain of Marek's disease virus. Proc. Natl. Acad. Sci. USA
97: 6091-6096
[Abstract]
[Full Text]
-
Liu, J.-L., Ye, Y., Qian, Z., Qian, Y., Templeton, D. J., Lee, L. F., Kung, H.-J.
(1999). Functional Interactions between Herpesvirus Oncoprotein MEQ and Cell Cycle Regulator CDK2. J. Virol.
73: 4208-4219
[Abstract]
[Full Text]
-
Parcells, M. S., Dienglewicz, R. L., Anderson, A. S., Morgan, R. W.
(1999). Recombinant Marek's Disease Virus (MDV)-Derived Lymphoblastoid Cell Lines: Regulation of a Marker Gene within the Context of the MDV Genome. J. Virol.
73: 1362-1373
[Abstract]
[Full Text]